B+
Bull case
25%
Probability
Target price
$12.50
Analysis reference price unavailable
Analysis 2026-09-19 · RankAlpha Sentiment Codex
VMD
Viemed HealthcareBNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$10.00
Analysis reference price unavailable
Analysis 2026-09-19 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$6.75
Analysis reference price unavailable
Analysis 2026-09-19 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-19
Recent news sentiment (30D)
-26.0
Negative
Company
-
Unavailable
Macro
-26.0
Negative
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+57.6
Score
AI commentary
Primary evidence is constructive on revenue, patient growth, cash generation, and the less capital-intensive mix, but the reduced EBITDA outlook keeps the interpretation mixed [#SEC-8K-2026-08-03]. Social coverage, options skew, short interest, employee sentiment, post-print analyst revisions, and a documented immediate market reaction are unavailable; zero values denote unavailable inputs rather than neutral readings. Sparse recent coverage and a loose peer set support a cautious, monitoring-style stance.
RankAlpha Sentiment Codex - 2026-09-19
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-31catalystFY2026 guidance delivery after mixed Q2 revisionHigh impact
Record Q2 revenue of $78.1 million and favorable operating trends supported a narrower $314–$320 million revenue range, but adjusted EBITDA guidance was reduced to $64–$68 million. Delivery against both ranges is the clearest near-term test of growth quality [#SEC-8K-2026-08-03].
2027-06-30catalystPAP and sleep-resupply scalingHigh impact
Q2 PAP patients increased 44.0% year over year and sleep-resupply patients increased 46.7%, supporting diversification toward less capital-intensive revenue. Sustained patient growth and cash conversion could improve the earnings mix [#SEC-8K-2026-08-03].
2027-06-30catalystHome-ventilation growth under revised CMS requirementsHigh impact
Management reported a record 12,635 ventilator patients, 4.5% sequential growth, and improved therapy compliance while operating under revised qualification, documentation, and utilization standards. Continued referral conversion and retention would validate adaptation to the coverage framework [#PR-EARNINGS-2026-08-11].
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-19 • Updated nightlySource: Internal modelMethodology